Celldex Therapeutics (CLDX) Competitors $24.45 -0.75 (-2.98%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$24.44 -0.01 (-0.04%) As of 09/12/2025 05:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CLDX vs. ALKS, LGND, FOLD, BCRX, MNKD, INVA, NVAX, DVAX, OPK, and GERNShould you be buying Celldex Therapeutics stock or one of its competitors? The main competitors of Celldex Therapeutics include Alkermes (ALKS), Ligand Pharmaceuticals (LGND), Amicus Therapeutics (FOLD), BioCryst Pharmaceuticals (BCRX), MannKind (MNKD), Innoviva (INVA), Novavax (NVAX), Dynavax Technologies (DVAX), OPKO Health (OPK), and Geron (GERN). These companies are all part of the "biotechnology" industry. Celldex Therapeutics vs. Its Competitors Alkermes Ligand Pharmaceuticals Amicus Therapeutics BioCryst Pharmaceuticals MannKind Innoviva Novavax Dynavax Technologies OPKO Health Geron Celldex Therapeutics (NASDAQ:CLDX) and Alkermes (NASDAQ:ALKS) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, risk, earnings, valuation, media sentiment and analyst recommendations. Do analysts recommend CLDX or ALKS? Celldex Therapeutics currently has a consensus price target of $46.67, suggesting a potential upside of 90.87%. Alkermes has a consensus price target of $41.85, suggesting a potential upside of 55.16%. Given Celldex Therapeutics' higher probable upside, analysts plainly believe Celldex Therapeutics is more favorable than Alkermes.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Celldex Therapeutics 0 Sell rating(s) 2 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.78Alkermes 0 Sell rating(s) 3 Hold rating(s) 8 Buy rating(s) 2 Strong Buy rating(s) 2.92 Do institutionals & insiders hold more shares of CLDX or ALKS? 95.2% of Alkermes shares are held by institutional investors. 4.4% of Celldex Therapeutics shares are held by insiders. Comparatively, 4.4% of Alkermes shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Is CLDX or ALKS more profitable? Alkermes has a net margin of 23.15% compared to Celldex Therapeutics' net margin of -3,446.88%. Alkermes' return on equity of 24.86% beat Celldex Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Celldex Therapeutics-3,446.88% -27.61% -26.20% Alkermes 23.15%24.86%17.14% Which has more risk and volatility, CLDX or ALKS? Celldex Therapeutics has a beta of 1.19, indicating that its stock price is 19% more volatile than the S&P 500. Comparatively, Alkermes has a beta of 0.53, indicating that its stock price is 47% less volatile than the S&P 500. Does the media favor CLDX or ALKS? In the previous week, Alkermes had 20 more articles in the media than Celldex Therapeutics. MarketBeat recorded 30 mentions for Alkermes and 10 mentions for Celldex Therapeutics. Celldex Therapeutics' average media sentiment score of 1.26 beat Alkermes' score of 0.54 indicating that Celldex Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Celldex Therapeutics 5 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Alkermes 9 Very Positive mention(s) 2 Positive mention(s) 13 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive Which has higher earnings & valuation, CLDX or ALKS? Alkermes has higher revenue and earnings than Celldex Therapeutics. Celldex Therapeutics is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCelldex Therapeutics$7.02M231.30-$157.86M-$3.01-8.12Alkermes$1.51B2.96$367.07M$2.0812.97 SummaryAlkermes beats Celldex Therapeutics on 12 of the 17 factors compared between the two stocks. Get Celldex Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CLDX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CLDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CLDX vs. The Competition Export to ExcelMetricCelldex TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.62B$3.15B$5.79B$10.19BDividend YieldN/A2.32%5.73%4.60%P/E Ratio-8.1221.4375.4026.02Price / Sales231.30419.38514.85113.09Price / CashN/A44.4425.8129.91Price / Book2.179.6112.166.25Net Income-$157.86M-$53.29M$3.29B$270.76M7 Day Performance6.91%0.13%0.74%3.87%1 Month Performance-1.96%5.55%5.00%5.49%1 Year Performance-44.63%10.44%62.55%25.86% Celldex Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CLDXCelldex Therapeutics2.3946 of 5 stars$24.45-3.0%$46.67+90.9%-44.6%$1.62B$7.02M-8.12150Positive NewsALKSAlkermes4.5467 of 5 stars$28.97+0.1%$41.08+41.8%-2.5%$4.78B$1.56B13.931,800Trending NewsAnalyst ForecastLGNDLigand Pharmaceuticals4.1948 of 5 stars$161.71+1.1%$165.17+2.1%+58.2%$3.17B$167.13M-40.4380Short Interest ↑FOLDAmicus Therapeutics3.9554 of 5 stars$7.59-0.8%$16.22+113.7%-29.3%$2.34B$528.29M-63.24480Positive NewsBCRXBioCryst Pharmaceuticals4.2534 of 5 stars$8.31-1.9%$16.70+101.0%-0.1%$1.74B$450.71M-46.16530Positive NewsMNKDMannKind4.4172 of 5 stars$4.59+2.2%$9.50+107.0%-11.2%$1.41B$285.50M41.73400Positive NewsShort Interest ↓INVAInnoviva4.771 of 5 stars$20.43+2.0%$42.75+109.3%-2.2%$1.29B$358.71M65.91100Positive NewsAnalyst DowngradeShort Interest ↓NVAXNovavax4.4812 of 5 stars$7.47-1.5%$14.29+91.2%-41.4%$1.21B$682.16M3.281,990Positive NewsDVAXDynavax Technologies4.4593 of 5 stars$10.12-1.5%$24.33+140.4%-15.8%$1.19B$277.25M-22.00350Positive NewsOPKOPKO Health4.3997 of 5 stars$1.38-2.8%$2.75+99.3%-10.8%$1.10B$713.10M-5.522,997GERNGeron3.1286 of 5 stars$1.40-2.1%$4.19+199.1%-71.8%$893.22M$76.99M-10.77229Positive News Related Companies and Tools Related Companies Alkermes Alternatives Ligand Pharmaceuticals Alternatives Amicus Therapeutics Alternatives BioCryst Pharmaceuticals Alternatives MannKind Alternatives Innoviva Alternatives Novavax Alternatives Dynavax Technologies Alternatives OPKO Health Alternatives Geron Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CLDX) was last updated on 9/14/2025 by MarketBeat.com Staff From Our PartnersREVEALED: Something Big Happening Behind White House Doorswhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredCollege grad makes $64,000 a monthA Wall Street legend just helped train our own proprietary AI system in the stock market (a project that took ...Stansberry Research | SponsoredCrypto Gets Official Government Backing—Here's the WinnerTrump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump’s right about Epstein.A crisis that could devastate your wealth, upend the dollar, and accelerate the collapse of America’s economy....Porter & Company | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredDo NOT Day Trade (Do THIS instead)Forget day trading (especially in markets like these). Trade OVERNIGHT instead! I've uncovered a shockin...Monument Traders Alliance | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Celldex Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Celldex Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
